Company: BLCO
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001860742-25-000023
Chunk: 82

Company: Bausch & Lomb Corp
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 8
Chunk 82
---
insVision Care$602 28 %$571 28 %$31 5 %Pharmaceuticals124 14 %200 23 %(76)(38)%Surgical3 — %28 5 %(25)(89)%Vision Care Segment ProfitThe Vision Care segment profit was $602 million and $571 million for the nine months ended September 30, 2025 and 2024, respectively, an increase of $31 million. The increase was primarily driven by the increase in revenue, partially offset by higher cost of sales, driven by our contact lens businesses and higher selling expense.

48

Pharmaceuticals Segment ProfitThe Pharmaceuticals segment profit was $124 million and $200 million for the nine months ended September 30, 2025 and 2024, respectively, a decrease of $76 million. The decrease was primarily driven by: (i) higher selling and advertising and promotional expenses related to MIEBO®, (ii) declines in the U.S. generics business, (iii) gross-to-net pricing pressures, primarily attributable to XIIDRA® and MIEBO® and (iv) higher R&D expense.Surgical Segment ProfitThe Surgical segment profit was $3 million and $28 million for the nine months ended September 30, 2025 and 2024, respectively, a decrease of $25 million. The decrease was primarily due to: (i) the overall impact of the voluntary recall of certain enVista IOL products and (ii) higher selling expenses, partially offset by the increase in revenues.Non-Operating Income and ExpenseInterest Expense Interest expense was $323 million and $301 million for the nine months ended September 30, 2025 and 2024, respectively, an increase of $22 million. The increase was primarily attributable to the write-off of financing costs associated with the June 2025 refinancing. See Note 10, “FINANCING ARRANGEMENTS” to our unaudited interim Condensed Consolidated Financial Statements for further details regarding our financing arrangements.Loss on Extinguishment of DebtLoss on extinguishment of debt was $6 million for the nine months ended September 30, 2025 and relates to our June 2025 refinancing.Foreign Exchange and OtherForeign exchange and other was a net loss of $11 million and $8 million for the nine months ended September 30, 2025 and 2024, respectively.Income TaxesBenefit from income taxes was $36 million for